TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 79 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $20,000 | -62.3% | 14,984 | 0.0% | 0.00% | -62.5% |
Q4 2018 | $53,000 | +29.3% | 14,984 | 0.0% | 0.01% | +33.3% |
Q3 2018 | $41,000 | -22.6% | 14,984 | 0.0% | 0.01% | -25.0% |
Q2 2018 | $53,000 | +15.2% | 14,984 | 0.0% | 0.01% | +14.3% |
Q1 2018 | $46,000 | -51.1% | 14,984 | 0.0% | 0.01% | -50.0% |
Q4 2017 | $94,000 | -7.8% | 14,984 | 0.0% | 0.01% | -12.5% |
Q3 2017 | $102,000 | -4.7% | 14,984 | 0.0% | 0.02% | -5.9% |
Q2 2017 | $107,000 | -22.5% | 14,984 | 0.0% | 0.02% | -22.7% |
Q1 2017 | $138,000 | +130.0% | 14,984 | 0.0% | 0.02% | +144.4% |
Q4 2016 | $60,000 | +106.9% | 14,984 | +100.0% | 0.01% | +125.0% |
Q3 2016 | $29,000 | -9.4% | 7,492 | 0.0% | 0.00% | -20.0% |
Q2 2016 | $32,000 | -8.6% | 7,492 | 0.0% | 0.01% | 0.0% |
Q1 2016 | $35,000 | -53.3% | 7,492 | 0.0% | 0.01% | -54.5% |
Q4 2015 | $75,000 | +33.9% | 7,492 | 0.0% | 0.01% | +22.2% |
Q3 2015 | $56,000 | -84.2% | 7,492 | 0.0% | 0.01% | -83.9% |
Q2 2015 | $355,000 | +624.5% | 7,492 | +66.5% | 0.06% | +600.0% |
Q1 2014 | $49,000 | – | 4,500 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 1,048,642 | $3,219,000 | 0.50% |
Virtus ETF Advisers LLC | 130,920 | $402,000 | 0.35% |
683 Capital Management, LLC | 600,000 | $1,842,000 | 0.16% |
Tekla Capital Management LLC | 859,322 | $2,638,000 | 0.10% |
DOW CHEMICAL CO /DE/ | 65,000 | $200,000 | 0.07% |
Alambic Investment Management, L.P. | 115,834 | $356,000 | 0.05% |
A.R.T. Advisors, LLC | 262,896 | $807,000 | 0.03% |
Candriam S.C.A. | 520,613 | $1,598,000 | 0.03% |
Man Group plc | 1,674,341 | $5,140,000 | 0.02% |
Baker Brothers Advisors | 935,000 | $2,870,000 | 0.02% |